Stockscreener 앱 받기
0.0865
5.98%
-0.0055
시간 외 거래:
.09
0.0035
+4.05%
전일 마감가:
$0.092
열려 있는:
$0.095
하루 거래량:
1.21M
Relative Volume:
1.12
시가총액:
$7.00M
수익:
$1.47M
순이익/손실:
$-97.61M
주가수익비율:
-0.0581
EPS:
-1.49
순현금흐름:
$-80.90M
1주 성능:
+1.88%
1개월 성능:
-47.58%
6개월 성능:
-62.84%
1년 성능:
-98.40%
1일 변동 폭
$0.085
$0.0952
1주일 범위
$0.0834
$0.1182
52주 변동 폭
$0.082
$5.65
Lyra Therapeutics Inc Stock (LYRA) Company Profile
명칭
Lyra Therapeutics Inc
전화
617-373-4600
주소
480 ARSENAL WAY, WATERTOWN, MA
LYRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.0865 | 7.00M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-05-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-05-06 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 재개 | BTIG Research | Buy |
| 2023-08-31 | 개시 | H.C. Wainwright | Buy |
| 2022-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 개시 | BTIG Research | Buy |
| 2020-05-26 | 개시 | BofA/Merrill | Buy |
| 2020-05-26 | 개시 | Jefferies | Buy |
| 2020-05-26 | 개시 | William Blair | Outperform |
모두보기
Lyra Therapeutics Inc 주식(LYRA)의 최신 뉴스
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World
Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - SETE News
Chronic Rhinosinusitis Pipeline 2024: FDA Updates, Therapy - openPR.com
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Dream Finders Homes (NASDAQ:DFH) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Comparing Lyra Therapeutics (NASDAQ:LYRA) & Anika Therapeutics (NASDAQ:ANIK) - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down on Disappointing Earnings - Defense World
Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Watch this stock’s price performance: Lyra Therapeutics Inc (NASDAQ:LYRA) - US Post News
Lyra Therapeutics Inc (LYRA) receives a Hold rating from Jefferies - Knox Daily
Examining the Potential Price Growth of Oshkosh Corp (OSK) - Knox Daily
Neuronetics Inc [STIM] Stock sold by Insider Furlong Stephen for $1122.0 - Knox Daily
BrightSpire Capital Inc [BRSP] Insider Activity: An Update for Investors - Knox Daily
LYRA’s 2023 Market Dance: Down -5.96% – Time to Invest? - The InvestChronicle
Lyra Therapeutics Inc (LYRA) Shares Rise Despite Market Challenges - The News Heater
TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
LYRA News Today | Why did Lyra Therapeutics stock go up today? - MarketBeat
Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register
New Outlook On ReNew Energy Global plc - Stocks Register
Open Lending Corp’s (LPRO) Stock Is Harder To Predict Than You Think - Stocks Register
Lyra Therapeutics Inc (LYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):